April 30th 2025
Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.
Interim Phase 2 Trial Results Show Quadruplet Regimen Tolerable, Effective in MM
June 25th 2022Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM).
Read More
Study Finds Environmental, Lifestyle Risk Factors of Atopic Dermatitis in Preschool Children
June 24th 2022Several environmental and lifestyle factors were associated with significant risk of atopic dermatitis development in preschool children of Shenzhen, China, including the presence of mold in the child’s room, living in a villa/townhouse, and using composite wood floors.
Read More
What’s Next in Health Care? Panelists Highlight Data, Partnerships Post-COVID-19
June 24th 2022Panelists of an AHIP 2022 session discussed how future policy, infrastructure, and investment strategies in public health will reinforce the efforts already made during the pandemic, with partnerships and engagement key to optimize innovation.
Read More
Supreme Court Overturns Roe v Wade, Turning Issue Back to States
June 24th 2022Reversing a landmark precedent, the Supreme Court voted Friday to overturn 1973’s Roe v Wade decision that guaranteed American women the constitutional right to an abortion, and at least 1 justice suggested that other precedents, such as the right to birth control, be reversed as well.
Read More
Meningococcal Vaccine Uptake Lagging Among People Living With HIV
June 23rd 2022The findings of this study, which used insurance claims data for patients 2 years and older to determine rates of meningococcal A, C, W, Y vaccine uptake, points to the need for more education, the authors said.
Read More
Study Highlights Need for Validated Blood Biomarkers in PAH
June 23rd 2022Collecting more than 3 decades’ worth of data, researchers determined that none of the identified blood biomarkers are accurate enough to take the place of current diagnostic approaches, either due to lack of data or lack of specificity.
Read More
Biologic Switching Patterns, Discontinuation in Psoriasis Investigated in New Study
June 22nd 2022An analysis of biologic drug use patterns in patients with psoriasis from Tuscany, Italy, associated etanercept with the highest frequency of switching to other biologics; secukinumab and ustekinumab were linked with the lowest risk.
Read More
Self-administration of Biologics Well Tolerated, Effective for Asthma and CRS With Nasal Polyps
June 22nd 2022The adequate safety and improved symptom burden observed with self-administration of biologic therapies at home for the management of severe asthma and chronic rhinosinusitis with nasal polyps suggests potential in shifting care away from the more costlier in-patient setting.
Read More
Generic Drug Savings Possibilities: $3.6 Billion to Medicare Using DTC Pricing
June 22nd 2022How much would have Medicare saved if it had the same ability to purchase generic drugs at the same price as individuals using direct-to-consumer (DTC) pharmacies like the Mark Cuban Cost Plus Drug Company? Billions, as it turns out.
Listen
Alignment Between Manufacturers, Payers Key to Improving Specialty Drug Affordability and Access
June 22nd 2022Panelists taking part in an AHIP 2022 session discuss collaborative strategies among payers, manufacturers, and policy makers to address challenges regarding affordability and access of novel disease modifying drugs entering the marketplace.
Read More
There Is More to Blame Than Tech for T1D Outcomes Disparities, Investigators Argue
June 21st 2022Investigators from the Pediatric Diabetes Center at Hassenfeld Children’s Hospital at NYU Langone investigated outcomes disparities as they related to diabetes technology use among youth living with type 1 diabetes (T1D).
Read More
Dr Debra Patt: Telemedicine’s Contribution to Cancer Care Robust and Meaningful
June 20th 2022Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how enhancements to telemedicine precipitated by the COVID-19 pandemic have made lasting and meaningful changes to oncology care, including that these care improvements will persist post pandemic.
Watch
Major Adverse Cardiac Events Related to ICI Treatment Explored in New Study
June 17th 2022Major adverse cardiac events are rare but serious in patients treated with immune checkpoint inhibitors (ICIs), and increased awareness is crucial to identify and treat these conditions in a timely manner.
Read More